Learn more

TOCAGEN INC

Overview
  • Total Patents
    116
  • GoodIP Patent Rank
    30,142
  • Filing trend
    ⇧ 20.0%
About

TOCAGEN INC has a total of 116 patent applications. It increased the IP activity by 20.0%. Its first patent ever was published in 2009. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are ADMEDUS VACCINES PTY LTD, PROTOKINETIX INC and ID LELYSTAD INST DIERHOUDERIJ.

Patent filings per year

Chart showing TOCAGEN INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Gruber Harry E 69
#2 Jolly Douglas J 67
#3 Lin Amy H 31
#4 Logg Christopher R 30
#5 Jolly Douglas 25
#6 Perez Omar 23
#7 Ostertag Derek G 19
#8 Ibanez Carlos 16
#9 Robbins Joan M 13
#10 Harry E Gruber 12

Latest patents

Publication Filing date Title
WO2020142780A1 Car t cell methods and constructs
WO2020102437A1 Recombinant vectors comprising genes for binding domains and secretable peptides
WO2017079695A1 Gene expression patterns to predict responsiveness to virotherapy in cancer indications
KR20180048743A 2A < / RTI > peptide.
US2016222412A1 Recombinant vector with stabilizing a-loop
CA2943640A1 A retroviral vector having immune-stimulating activity
WO2015021077A1 Recombinant vector with optimized a-bulge
US2016175388A1 Immunosuppressive components associated with retroviral replicating vectors
US2014178340A1 Cancer combination therapy and recombinant vectors
WO2014066700A1 Retroviral vector with mini-promoter cassette
AU2013205006A1 Gene Therapy Vectors and Cytosine Deaminases
AU2013205004A1 Formulations of 5-fluorocytosine and Uses Thereof
EP2632491A2 Enhanced cancer treatment and monitoring using recombinant vectors
EP2633321A2 Antisera assays for mlv related viruses in humans and other mammals
CN103140581A Retrovirus detection
EP2547353A2 Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase.
CN107129971A The production cell of science retroviral vector
UA104298C2 Vectors for gene therapy and cytosine deaminases
MX2011003039A Gene therapy vectors and cytosine deaminases.
AU2009267052A1 Formulations of 5-fluorocytosine and uses thereof